title: Alkylation of myotoxic phospholipases A2 in Bothrops moojeni venom: a promising approach to an enhanced antivenom production.
abstract: Bothrops moojeni crude venom (MjCV) and its two major toxins, namely myotoxin I (MjTX-I) and myotoxin II (MjTX-II) were alkylated by p-bromophenacyl bromide (BPB). After alkylation the i.p. LD(50) (mice) of MjCV and MjTX-I/II increased from 6.0 to 15.7mg/kg and from 8.0 to 45.0mg/kg, respectively. In addition, doses of 5x LD(50) of alkylated MjTX-I did not cause a single death in mice and no myonecrosis was detected for the alkylated toxins, although both proteins still induced edema. Antibodies to native and modified crude venom or myotoxins cross-reacted with 12 purified class II myotoxic phospholipases A(2) found in snake venoms of the genus Bothrops. Myotoxic PLA(2)s from class I and class III were not recognized by the above antibodies. These results suggest that the overall antigenic structure is conserved among class II myotoxic PLA(2)s, despite differences in their amino acid sequences. Anti-MjTX-I-BPB and anti-MjTX-II-BPB rabbit serum, obtained against the modified myotoxins, were apparently more efficient than those obtained against the native myotoxins. In neutralization experiments, pre-incubation of crude venom or isolated myotoxins with antibodies raised against the native or modified toxins inhibited their PLA(2) and myotoxic activities. Therefore, alkylation of His48 by BPB strongly reduces the local tissue damage induced by B. moojeni venom or isolated myotoxins while retaining antigenicity, which suggests a promising procedure for an enhanced antiophidian serum production for practical purposes.
authors.affiliation: Departamento de Biotecnologia, Universidade de Ribeirão Preto, UNAERP, SP, Ribeirão Preto, Brazil.
authors.forename: Andreimar M
authors.initials: AM
authors.lastname: Soares
authors.forename: Wladimir P
authors.initials: WP
authors.lastname: Sestito
authors.forename: Silvana
authors.initials: S
authors.lastname: Marcussi
authors.forename: Rodrigo G
authors.initials: RG
authors.lastname: Stábeli
authors.forename: Silvia H
authors.initials: SH
authors.lastname: Andrião-Escarso
authors.forename: Odete A B
authors.initials: OA
authors.lastname: Cunha
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Vieira
authors.forename: José R
authors.initials: JR
authors.lastname: Giglio
mesh_terms: D000818:Animals; D000997:Antivenins / Q000494:pharmacology*; D017837:Bothrops / Q000378:metabolism*; D002417:Cattle; D003435:Crotalid Venoms / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004487:Edema; D054501:Group II Phospholipases A2; D007120:Immunochemistry; D005779:Immunodiffusion; D007124:Immunoenzyme Techniques; D008297:Male; D051379:Mice; D009498:Neurotoxins / Q000737:chemistry* / Q000378:metabolism; D010741:Phospholipases A / Q000737:chemistry* / Q000378:metabolism*; D030162:Reptilian Proteins
chemical_list: D000997:Antivenins; D003435:Crotalid Venoms; D009498:Neurotoxins; D030162:Reptilian Proteins; C114084:myotoxin II, Bothrops moojeni; D010741:Phospholipases A; D054501:Group II Phospholipases A2; C076780:myotoxin I